secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093932
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M
--------------------------------------------------------------------------------

- Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.
- Q2 2024 net loss of $8.6M ($0.19 per share) vs net loss of $7.7M ($0.27) in Q2 2023.
- Cash and cash equivalents totaled $10.2M as of June 30, 2024, down from $21.3M at Dec 31, 2023.
- Phase 1 INB-100 data: 100% 1-year complete remission in evaluable patients; two patients relapse-free over 3.5 years.
- Phase 1 INB-200: 92% of GBM patients exceeded median PFS of 7 months; no cell therapy-related toxicities observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/0000950170-24-093932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/inab-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer